复方萘酚喹片治疗恶性疟的临床观察

CLINICAL TRIAL OF CO-NAPHTHOQUINE IN THE TREATMENT OF FALCIPARUM MALARIA

目的 临床观察复方萘酚喹片对恶性疟的疗效和安全性。 方法 在海南省疟疾流行区共收治恶性疟病人32 0例 ,其中 10 0例病人进行了血常规、血生化、尿、心电图等指标的检测。患者一次口服复方萘酚喹片 14 0 0 mg,住院 3～ 7d,随访 2 8d。 结果 收治的 32 0例中 ,2 8d治愈率为 97.5 % (312 /32 0 ) ,有 8例复燃。平均退热时间为 (17.5±11.4 ) h,2 4 h原虫下降率为 (97.3± 8.8) % ,原虫转阴时间为 (2 9.9± 8.7) h,临床及实验室检查均未见明显不良反应。 结论 复方萘酚喹片是一个高效、速效、服药简便且安全的新复方抗疟药。

Objective To observe the efficacy and safety of co-naphthoquine for the treatment of faciparum malaria. Methods 320 patients in Hainan Province, each with naturally acquired, symptomatic Plasmodium falciparum infection were selected as the subjects, treated with a single dose of co-naphthoquine 1 400 mg. 100 of the 320 patients were examined by hematology, blood biochemistry, urine analysis and ECG. The patients were hospitalized for 3-7 days and followed up for 28 days. Results 312 of the 320 patients were shown to be free of infection at 28 days, a 97.5% cure rate. The mean fever clearance time was (17.5±11.4) h; the mean parasite clearance time was (29.9±8.7) h. No significant adverse effects were encountered. Conclusion Co-naphthoquine possesses benefits of both naphthoquine and artemisinine, being rapid onset of action, high cure rate, a short course of only one dose and is well tolerated in patients.